Memantine and Antipsychotics Use

Prospective, Single-arm, Multi-centre, Open-label Study to Investigate the Potential to Reduce Concomitant Antipsychotics Use in Patients With Moderate to Severe Dementia of Alzheimer's Type (DAT) Treated With Memantine

To investigate the potential to reduce concomitant antipsychotic medication use in subjects with moderate dementia of Alzheimer's type, treated with memantine.

Inclusion criteria:

• Current diagnosis of probable Alzheimer's disease consistent with NINCDS-ADRDA criteria or with DSM IV TR criteria for Dementia of the Alzheimer's type.
• MRI or CT scan supporting the diagnosis of DAT without indications of any relevant other CNS disorders.
• Patients treated with any acetylcholinesterase inhibitor (AChEI) man be included.
• The patient should have German as a mother-tongue or at least speak the language fluently.

Exclusion criteria:

• Evidence (including CT/MRI results) of any clinically significant central nervous system disease other than Alzheimer's disease.
• Modified Hachinski Ischemia score greater than 4 at screening.
• Intake of any medication that is contra-indicated in combination with memantine.
• Treatment with depot antipsychotics.
• History of severe drug allergy, or hypersensitivity, or patients with known hypersensitivity to memantine, amantadine or lactose.
• Known or suspected history of alcoholism or drug abuse within the past 10 years.
• Previous treatment with memantine or participation in an investigational study with memantine.